16Aug 2023
Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations

Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate‐specific antigen concentrations

This study investigated the outcomes of nonmetastatic prostate cancer (nmPCa) patients with elevated prostate-specific antigen (PSA) levels, known to increase metastasis risk, who underwent radical prostatectomy (RP) or radiotherapy (RT). Using SEER data from 2004 to 2015, 6,177 nmPCa patients with PSA ≥50 ng/mL were analyzed; 27% had PSA ≥98 ng/mL. Over a median follow-up of 113 months, 5-year and 10-year cancer-specific survival (CSS) rates were 92.3% and 81.5%, respectively; overall survival (OS) was 61%. For PSA ≥98 ng/mL subgroup, 5-year and 10-year CSS were 89.2% and 76%. Factors associated with improved CSS included ISUP grade, N stage, RP treatment, and age. High PSA levels shouldn't exclude radical local therapy.

  • #urology

Like

Save

Share